Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 12/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.47 |
| ▸ | FAP | Q12884 | 5/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.45 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.45 |
| ▸ | GRB2 | P62993 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17867011 | 1.00 | XIAP (0.74) | XIAPPOLBDPP4DPP7FAP | |
| Diprotin A SCHEMBL6404766 | 0.94 | XIAP (0.72) | XIAPPOLBDPP4DPP7FAP | |
| Diprotin A SCHEMBL17867000 | 0.94 | XIAP (0.72) | XIAPPOLBDPP4DPP7FAP | |
| SCHEMBL29433188 | 0.91 | XIAP (0.67) | XIAPPOLBDPP4DPP7FAP | |
| SCHEMBL31256939 | 0.91 | XIAP (0.62) | XIAPPOLBDPP4DPP7FAP | |
| SCHEMBL30052704 | 0.91 | XIAP (0.77) | XIAPPOLBDPP4DPP7FAP | |
| SCHEMBL29641757 | 0.89 | XIAP (0.58) | XIAPDPP4DPP7FAPDPP8 | |
| SCHEMBL31257009 | 0.89 | XIAP (0.60) | XIAPGRB2 | |
| SCHEMBL31257087 | 0.88 | XIAP (0.59) | XIAPPOLBGRB2LNPEP | |
| SCHEMBL30069149 | 0.87 | XIAP (0.63) | XIAPPOLBDPP4DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| CN-116283702-B | Compound with antidiabetic activity and preparation method and application thereof | 西南医科大学 | 2025-06-03 | — | — | CN | disclosed |
| CN-120058836-A | Compound with antidiabetic activity and application thereof | 西南医科大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-116283702-A | Compound with antidiabetic activity and preparation method and application thereof | 西南医科大学 | 2023-06-23 | — | — | CN | disclosed |
| US-20230151057-A1 | LACTIC ACID BACTERIA GROWTH PROMOTER | ASAHI GROUP HOLDINGS, LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-114213504-B | Compound with antidiabetic activity and application thereof | 西南医科大学 | 2023-05-09 | — | — | CN | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-114213504-A | Compound with anti-diabetic activity and application thereof | 西南医科大学 | 2022-03-22 | — | — | CN | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | XIAP 4043/4885POLB 1787/4885DPP4 43/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | XIAP 2121/4885POLB 2157/4885DPP4 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.